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The climate for commercial biotechnology in several developing countries is improving. As a result of 
the growing science base, biotechnology companies can successfully be located and thrive in these 
countries. The rewards which can flow from the successful exploitation of research should encourage 
investment in biotechnological activities.  
 





The biotechnological revolution has been characterized 
by the rapid pace of discovery in the biological sciences, 
and a tremendous impact on both fundamental and 
applied research. Biotechnology is multidisciplinary 
encompassing microbiology, chemistry, biochemistry, 
genetics, molecular biology, immunology, cell and tissue 
culture and physiology, as well as engineering. 
Proponents around the world project a positive future in 
which biotechnology overcomes food shortages, 
improves the environment, heals or eliminates disease 
and leads to a prosperous and healthy society. 
 
 
PRODUCTS AND PROSPECTS 
 
Products and services that are derived from 
biotechnology has been the driving force behind the 
establishment of biotechnology companies. For the 
pharmaceutical sector, these products include 
recombinant vaccines, hormones, vitamins and 
antibiotics. In plant biotechnology, engineering for insect 
and disease resistance, as well as storage protein and 
other nutritional improvements has been the trend. 
Furthermore, potential benefits from tissue culture, bio-
fertilizers, bio-pesticides, and medicinal plants are 
tremendous. Plants also have considerable potential for 
the production of biopharmaceutical products because 
they can be genetically transformed. Delivery of a 
biopharmaceutical product by direct ingestion of the 
modified plant removing the need for purification is very 
promising. Such biopharmaceutical proteins and edible 
vaccines can be stored and distributed as seeds, tubers, 
or fruits, making immunization programs in developing 
countries cheaper and potentially easier to administer.  
Efficient sewage treatment and degradation of 
petroleum and management of oil spills by genetically 
modified microorganisms can be being applied to 
improve the environment. Industrial biotechnology has 
evolved as a significant manufacturing tool for products 
like fuel-grade ethanol, organic acids and bulk amino 
acids. Current development projects within the chemical 
industry, including lactic acid and biodegradable plastics, 
indicate that new biotechnological processes and 
products may soon approach the market place as 
alternatives to petrochemical products.  
Developing countries are already benefiting and should 
continue to benefit significantly from advances in plant 
biotechnology. Insect-protected cotton containing a 
natural insecticide protein from Bacillus thuringiensis (Bt 
cotton) is providing millions of farmers with increased 
yields, reduced insecticide costs and fewer health risks. 
Many other useful plant biotechnology products  that  can  




benefit poor farmers and consumers are in the research 
and development pipelines of institutions in developing 
countries, and should soon reach farmers' fields. 
 
 
INVESTING IN BIOTECHNOLOGY 
 
The original investment in basic science research has 
delivered truly incredible dividends. Through the creation 
of highly skilled jobs and contribution of billion of dollars 
to western economies, biotechnology provides the 
promise to vastly improve the quality of life. The new 
knowledge generated by investment in biotechnology 
research has led to a bounty of potential applications for 
improvement of health, which are being explored for 
commercial purposes by the biotechnology industry. This 
success can be attributed to the collaboration between 
industry and academia.  
After a slow start, many developing countries are now 
investing in agricultural biotechnology. Although these 
countries face several constraints, efforts are being made 
to promote biotechnology that requires high investment 
with long-term returns. Nevertheless, more public 
investment is needed, as well as new and imaginative 
public-private collaboration to make this knowledge 
beneficial. Biotechnology research is now done in 
universities and research institutes in developing 
countries, and the number of academic degrees awarded 
in this field has increased in recent years. Furthermore, 
several scientists from developing countries have 
acquired biotechnology expertise, and most have been 
actively involved in the research in laboratories in 
western countries. A strong science base is one of the 
strongest factors for start-ups in life sciences. Most of 
these start-ups spin out from universities, and research 
institutes.  
The requirement of adequate infrastructure is a critical 
factor for the establishment of biotechnology companies. 
This includes laboratory facilities, research equipments 
and other physical aspects. Additional factors such as 
management support and pilot plant facilities are also 
significant. While research and development budgets for 
biotechnology research are only beginning to pick up in 
developing countries, start-up funding for biotechnology 
companies is still very rare to come-by. Financing early 
stages of business development could be achieved 
through seed funding, easier access to loans and venture 
funds. Specific biotechnology funds supported by 
governments and international agencies, and dedicated 
to investment in biosciences and biotechnology 
companies will have a real impact.  
Business incubators are unique in stimulating spin-offs 
from universities and research institutes, and offering 
young companies a dedicated space to develop their 
activities during the first years. However, such incubators 
are still very uncommon in developing countries. These 





businesses, are becoming a vital strategy for nurturing 
young businesses. Biotechnology clusters that shares 
facilities and provides a supportive environment is 
another good strategy for commercializing research. 
Furthermore, access to patents at affordable license fees 
and relaxed biotechnology regulations will encourage 
young companies and investors. Tax assistance to build 
laboratories and to offset the long-term losses associated 
with biotechnology research is an important incentive for 
investors. This would be particularly important for smaller 
companies that must invest years of research before 
getting to the payoff of a successful product. 
The often-emphasized negative view of biotechnology 
especially about genetically modified organisms in most 
developing countries’ newspapers will surely hurt 
biotechnology innovation and acceptability. To counteract 
this, researchers should be more involved in societal 




THE BIOTECHNOLOGY ENTREPRENEUR 
 
Biotechnology has a major impact on almost all major 
sectors of industry and represents a major element in the 
transition from an agricultural-based to a knowledge-
based economy. Nevertheless, the development of 
improved technology for agricultural production and its 
diffusion to farmers is a process requiring investment and 
time. In industrialized countries, biotechnology is viewed 
as an all-pervasive profit-generating technology and a 
strategic component of industrial competitiveness. In 
developing countries, the translation of this science base 
into commercial business is very much needed. There 
are so many products imported in several developing 
countries that can now be manufactured using 
biotechnology. Moreover, several developing countries 
have strategic advantages in some natural biological 
resources that can be exploited for their development. 
The challenge is to ensure that these ideas are 
marketable as value-added products. 
At the forefront to exploit biotechnology in developing 
countries should be the entrepreneurial scientist. Such a 
person should have both research and management 
skills including marketing and intellectual property rights, 
and understanding of scientific regulatory and ethical 
issues. Biotechnology has been the path by which a 
number of scientists, researchers and investors have 
boosted their wealth over the past year. Some of the 
activities waiting to happen include: 
 
1. Taking the results and products of government or 
international research and creating services around 
discovery or producing such products in commercial 
quantities. For example, multiplying improved seeds 
for sale to farmers.  





biotechnology companies to exploit the unique 
features in developing countries such as medicinal 
plants or genetically modification of profitable crops.  
3. Genetic (DNA) testing, quality control and 
environmental assessment. Application of DNA 
fingerprinting for identification of parents or solving 
crime is also a fast growing area of biotechnology. 
4. Other auxiliary companies and institutes such as 
biotechnology training and meeting centers, 
publications, venture capital firms and consulting. 
 
In recent years, the researcher-entrepreneur has become 
a role model in research institutions and business circles. 
Formerly, most of these researcher-entrepreneurs who 
set up their own companies were scientists who had 
achieved recognition. But today, most are younger 
researchers who have specialist knowledge and are 
attracted by the capitalist adventure. Therefore, to 
support the acquisition of such specialist knowledge in 
developing countries, courses with emphasis in molecular 
biology, genomics, proteomics, bioimaging, and 
bioinformatics must be included in the curriculum. 
Biotechnology business-related courses will also provide 
students an introduction to the complexities and unique 
problems of entrepreneurship. There is need for would-be 
entrepreneurs to be exposed to the topics most critical to 
successfully founding, financing and operating a 
biotechnology company. Hence, universities should let 
role models give entrepreneurial courses especially to 
scientists, provide biotechnology enterprise fellowships, 






Biotechnology is now one of the hot areas driving the 
stock markets as well as a frontier of knowledge and job 
creation. Just as the provision of research grants is a 
major issue, entrepreneurship and financing for 
biotechnology companies should also be high on 
government policy and educational agenda. 
Biotechnology can only be entrenched in developing 
countries with the establishment of a strong research 
base and entrepreneurial culture. Developing countries’ 
scientists who summon enough courage to take part in 
these ventures will become part of the business elite of 
the future. Finally, any country that can assist its 
scientists and entrepreneurs in successful biotechnology 
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